Gyre Therapeutics (GYRE) Current Assets (2010 - 2026)

Gyre Therapeutics (GYRE) has reported Current Assets for 17 consecutive years, with $91.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 34.02% year-over-year to $91.7 million; the TTM figure through Mar 2026 stood at $91.7 million (up 34.02% YoY), while the FY2025 annual figure was $102.4 million, up 58.01% from the prior year.
• Current Assets retreated to $91.7 million in Q1 2026 per GYRE's latest filing, from $102.4 million in the prior quarter.
• Across five years, Current Assets topped out at $102.4 million in Q4 2025 and bottomed at $5.1 million in Q3 2023.
• Historically, Current Assets has averaged $57.1 million across 5 years, with a median of $57.2 million in 2023.
• Annual changes were most pronounced in 2023 — Current Assets sank 90.63% — and 2024, when it soared 967.99%.
• Gyre Therapeutics' Current Assets stood at $49.7 million in 2022, then climbed by 15.24% to $57.2 million in 2023, then climbed by 13.22% to $64.8 million in 2024, then soared by 58.01% to $102.4 million in 2025, then dropped by 10.39% to $91.7 million in 2026.
• Business Quant data shows GYRE's Current Assets at $91.7 million in Q1 2026, $102.4 million in Q4 2025, and $98.6 million in Q3 2025.